PDC*line, our proprietary allogeneic cell line of Plasmacytoid Dendritic Cells solves the industrial limitations faced by immunotherapies based on dendritic cells currently on the market or in clinical development. Additionally PDC*line is much more potent than conventional dendritic cells to expand anti-tumor CD8+ T cells in vitro.
![](/sites/default/files/styles/wide/public/images/image-technology_0.png?itok=dqXE0T-l)